Sicart Associates LLC increased its holdings in shares of Alkermes Plc (NASDAQ:ALKS) by 92.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 12,500 shares of the company’s stock after buying an additional 6,000 shares during the quarter. Sicart Associates LLC’s holdings in Alkermes were worth $684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Toronto Dominion Bank boosted its stake in Alkermes by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the period. Quantbot Technologies LP acquired a new stake in Alkermes during the 3rd quarter worth $126,000. Virtu Financial LLC acquired a new stake in Alkermes during the 3rd quarter worth $201,000. Dynamic Technology Lab Private Ltd acquired a new stake in Alkermes during the 3rd quarter worth $214,000. Finally, Trexquant Investment LP acquired a new stake in Alkermes during the 3rd quarter worth $218,000. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Alkermes Plc (NASDAQ:ALKS) traded up $0.50 during mid-day trading on Wednesday, hitting $57.07. 472,176 shares of the stock traded hands, compared to its average volume of 944,860. Alkermes Plc has a one year low of $46.42 and a one year high of $63.40. The firm has a market cap of $8,650.00, a PE ratio of -51.41 and a beta of 2.13. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72.

Alkermes (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business’s revenue was up 20.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.09) EPS. equities research analysts forecast that Alkermes Plc will post -0.59 earnings per share for the current year.

A number of analysts recently weighed in on ALKS shares. Mizuho set a $81.00 price target on shares of Alkermes and gave the stock a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a research note on Monday, January 8th. Credit Suisse Group set a $66.00 price target on shares of Alkermes and gave the stock a “buy” rating in a research note on Tuesday, November 28th. ValuEngine cut shares of Alkermes from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Finally, UBS Group set a $54.00 price target on shares of Alkermes and gave the stock a “hold” rating in a research note on Friday, October 27th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $63.33.

In other news, insider Shane Cooke sold 6,207 shares of the stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $60.22, for a total value of $373,785.54. Following the completion of the transaction, the insider now owns 80,915 shares in the company, valued at approximately $4,872,701.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Landine sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the transaction, the senior vice president now owns 178,693 shares of the company’s stock, valued at approximately $8,704,136.03. The disclosure for this sale can be found here. Insiders sold a total of 142,624 shares of company stock valued at $7,633,176 in the last quarter. Insiders own 5.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/17/sicart-associates-llc-acquires-6000-shares-of-alkermes-plc-alks.html.

Alkermes Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.